<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705312</url>
  </required_header>
  <id_info>
    <org_study_id>2019-2458</org_study_id>
    <nct_id>NCT03705312</nct_id>
  </id_info>
  <brief_title>MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR</brief_title>
  <acronym>EVOLVE-MR</acronym>
  <official_title>EValuation of Outcomes of Transcatheter Mitral Valve Repair for the Treatment of Low Ejection Fraction and Moderate Functional Mitral ValvE Regurgitation In Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of transcatheter mitral valve repair with the MitraClip
      device to medical treatment in patients with heart failure and moderate functional mitral
      regurgitation to determine the impact of left ventricular remodelling and patients'
      functional capacity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Moderate mitral regurgitation in patients with LV dysfunction is associated with increased
      risk of death and hospitalizations for heart failure (HF) and leads to progressive
      remodelling of an already damaged left ventricle. Medical therapies and cardiac
      resynchronization therapy (CRT) have demonstrated favourable effects on LV remodelling in
      heart failure patients.

      Given the benefits and safety of transcatheter mitral valve repair with the MitraClip device
      in severe MR, it is conceivable that this technology could also be safely used in those with
      moderate MR to reduce mitral regurgitation, improve symptoms and result in LV remodelling. At
      present, the optimal treatment strategy for heart failure patients and moderate (2+, 2-3+)
      mitral regurgitation is uncertain therefore the EVOLVE-MR study proposes to evaluate
      transcatheter mitral valve repair with the MitraClip in such patients to study the effects on
      LV remodelling and functional capacity.

      EVOLVE-MR is a randomized study of MitraClip and medical therapy in symptomatic heart failure
      patients with moderate (2+, 2-3+) secondary mitral regurgitation. The objective of this study
      is to determine the impact of both therapies on left ventricular remodelling and functional
      capacity of the target patient population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1 to medical treatment or intervention with the MitraClip device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular diastolic remodelling</measure>
    <time_frame>12 months</time_frame>
    <description>Change in indexed left ventricular diastolic volume (LVEDV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional capacity as measured by 6 minute walk test</measure>
    <time_frame>12 months</time_frame>
    <description>Change in distance walked on six-minute walk test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation Severity (RV)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in mitral regurgitant volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation Severity (EROA)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in effective regurgitant orifice area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measurement</measure>
    <time_frame>12 months</time_frame>
    <description>Change in indices of quality of life as measured by Kansas City Cardiomyopathy Questionnaire. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Heart Failure</condition>
  <condition>Mitral Valve Regurgitation Due to Cardiomyopathy (Disorder)</condition>
  <arm_group>
    <arm_group_label>Guideline-directed medical therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard guideline-directed medical treatment for heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcatheter Mitral valve repair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MitraClip treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter mitral valve repair</intervention_name>
    <description>Transcatheter mitral valve repair performed using the MitraClip device</description>
    <arm_group_label>Transcatheter Mitral valve repair</arm_group_label>
    <other_name>MitraClip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Guideline-directed medical therapy</intervention_name>
    <description>Standard medical therapy for heart failure as recommended by HF guidelines</description>
    <arm_group_label>Guideline-directed medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate functional mitral regurgitation (2+, 2-3+)

          -  Left ventricular ejection fraction &gt;20%

          -  LVEDV 75-110 ml/m2

          -  Symptomatic heart failure (NYHA Class II-IV)

        Exclusion Criteria:

          -  Left ventricular ejection fraction &lt; 20%

          -  Severe functional mitral regurgitation

          -  Recent coronary artery bypass graft surgery (CABG)

          -  Untreated significant coronary artery disease

          -  Mitral valve area &lt; 4.0cm2

          -  Severe pulmonary hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita W Asgar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anique Ducharme, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean L Rouleau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anita W Asgar, MD</last_name>
    <phone>5143763330</phone>
    <phone_ext>3800</phone_ext>
    <email>anita.asgar@umontreal.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita W Asgar, MD</last_name>
      <phone>5143763330</phone>
      <email>anita.asgar@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitral regurgitation</keyword>
  <keyword>transcatheter mitral valve repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

